Avila Therapeutics Presents Clinical and Preclinical Data on AVL-292 Showing Potential for the Treatment of Autoimmune Disease at the 2011 American College of Rheumatology Annual Scientific Meeting
11/8/2011 7:21:05 AM
BEDFORD, Mass.--(BUSINESS WIRE)--Avila Therapeutics, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced today the presentation of data on AVL-292, a clinical-stage inhibitor of Bruton's tyrosine kinase (Btk), at the 2011 American College of Rheumatology (ACR) annual scientific meeting in Chicago, IL. The data demonstrate that the potent and selective covalent inhibition of Btk by AVL-292 results in sustained therapeutic effects in models of rheumatoid arthritis. Furthermore, the safety and pharmacokinetic and pharmacodynamic attributes in human volunteers show the potential of AVL-292 to deliver substantial clinical benefit for patients suffering from B-cell mediated autoimmune diseases.